

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2026
Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____.
Commission File Number 001-33092

LEMAITRE VASCULAR, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
63 Second Avenue, Burlington, Massachusetts
(Address of principal executive offices)

04-2825458
(I.R.S. Employer
Identification No.)
01803
(Zip Code)

(781) 221-2266
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.01 par value per share	LMAT	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 2, 2026, the registrant had 22,869,257 shares of common stock, par value \$.01 per share, outstanding.

LEMAITRE VASCULAR
FORM 10-Q
TABLE OF CONTENTS

	Page
<u>Part I. Financial Information:</u>	1
<u>Item 1. Financial Statements</u>	1
<u>Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 2025</u>	1
<u>Unaudited Consolidated Statements of Operations for the three-month and six-month periods ended June 30, 2026 and 2025</u>	2
<u>Unaudited Consolidated Statements of Comprehensive Income for the three-month and six-month periods ended June 30, 2026 and 2025</u>	3
<u>Unaudited Consolidated Statements of Stockholders' Equity for the three-month and six-month periods ended June 30, 2026 and 2025</u>	4
<u>Unaudited Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2026 and 2025</u>	5
<u>Notes to Unaudited Consolidated Financial Statements</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosure about Market Risk</u>	27
<u>Item 4. Controls and Procedures</u>	27
<u>Part II. Other Information:</u>	29
<u>Item 1. Legal Proceedings</u>	29
<u>Item 1A. Risk Factors</u>	29
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
<u>Item 5. Other Information</u>	30
<u>Item 6. Exhibits</u>	31
<u>Signatures</u>	32

Part I. Financial Information

Item 1. Financial Statements

LeMaitre Vascular, Inc. Consolidated Balance Sheets

	(unaudited) June 30, 2026	December 31, 2025
	(in thousands, except share data)	
Assets		
Current assets:		
Cash and cash equivalents	\$ 26,625	\$ 28,244
Short-term marketable securities	349,615	330,876
Accounts receivable, net of allowances of \$1,327 at June 30, 2026 and \$1,400 at December 31, 2025	35,682	33,610
Inventory and other deferred costs	70,503	70,422
Prepaid expenses and other current assets	5,872	5,080
Total current assets	488,297	468,232
Property and equipment, net	29,591	26,997
Right-of-use leased assets	19,998	15,762
Goodwill	65,945	65,945
Other intangibles, net	30,544	33,089
Deferred tax assets	734	759
Other assets	5,440	4,906
Total assets	\$ 640,549	\$ 615,690
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 3,236	\$ 3,646
Accrued expenses	22,880	29,411
Acquisition-related obligations	380	322
Lease liabilities - short-term	3,439	2,944
Total current liabilities	29,935	36,323
Convertible senior notes, net	169,091	168,645
Lease liabilities - long-term	17,724	14,003
Deferred tax liabilities	1,998	1,735
Other long-term liabilities	1,459	1,468
Total liabilities	220,207	222,174
Stockholders' equity:		
Preferred stock, \$0.01 par value; 3,000,000 shares authorized; none issued and outstanding	—	—
Common stock, \$0.01 par value; 37,000,000 shares authorized, 24,494,202 and 24,396,904 shares issued, 22,864,935 and 22,772,607 shares outstanding, respectively	245	244
Additional paid-in capital	236,161	228,407
Retained earnings	206,017	184,715
Accumulated other comprehensive loss	(4,165)	(2,411)
Treasury stock, at cost; 1,629,267 and 1,624,297 shares, respectively	(17,916)	(17,439)
Total stockholders' equity	420,342	393,516
Total liabilities and stockholders' equity	\$ 640,549	\$ 615,690

See accompanying notes to consolidated financial statements.

LeMaitre Vascular, Inc.

Consolidated Statements of Operations
(unaudited)

	Three months ended		Six months ended	
	June 30,		June 30,	
	2026	2025	2026	2025
	(in thousands, except per share data)		(in thousands, except per share data)	
Net sales	\$ 70,382	\$ 64,232	\$ 136,933	\$ 124,103
Cost of sales	19,618	19,258	37,773	37,709
Gross profit	50,764	44,974	99,160	86,394
Sales and marketing	14,408	14,895	28,923	29,107
General and administrative	11,110	10,396	23,156	20,883
Research and development	4,847	3,541	8,907	7,636
Total operating expenses	30,365	28,832	60,986	57,626
Income from operations	20,399	16,142	38,174	28,768
Other income (expense):				
Investment income	3,386	2,980	6,710	5,883
Interest expense	(1,302)	(1,299)	(2,602)	(2,589)
Other (loss) income, net	(294)	247	(421)	249
Income before income taxes	22,189	18,070	41,861	32,311
Provision for income taxes	5,139	4,291	9,132	7,521
Net income	\$ 17,050	\$ 13,779	\$ 32,729	\$ 24,790
Earnings per share of common stock:				
Basic	\$ 0.75	\$ 0.61	\$ 1.43	\$ 1.10
Diluted	\$ 0.74	\$ 0.60	\$ 1.42	\$ 1.08
Weighted-average shares outstanding:				
Basic	22,858	22,614	22,830	22,592
Diluted	24,531	22,892	24,505	22,896
Cash dividends declared per common share	\$ 0.25	\$ 0.20	\$ 0.50	\$ 0.40

See accompanying notes to consolidated financial statements.

LeMaitre Vascular, Inc.
Consolidated Statements of Comprehensive Income
(unaudited)

	Three months ended		Six months ended	
	June 30,		June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Net income	\$ 17,050	\$ 13,779	\$ 32,729	\$ 24,790
Other comprehensive income (loss):				
Foreign currency translation adjustment, net	(187)	2,011	(746)	2,839
Unrealized (loss) gain on marketable securities	(121)	144	(1,008)	347
Total other comprehensive (loss) income	(308)	2,155	(1,754)	3,186
Comprehensive income	<u>\$ 16,742</u>	<u>\$ 15,934</u>	<u>\$ 30,975</u>	<u>\$ 27,976</u>

See accompanying notes to consolidated financial statements.

LeMaitre Vascular, Inc.
Consolidated Statements of Stockholders' Equity
(unaudited)
(dollars in thousands)

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensiv e Income (Loss)	Treasury Stock		Total Stockholders' Equity
	Shares	Amount				Shares	Amount	
Balance at December 31, 2025	24,396,904	\$ 244	\$ 228,407	\$ 184,715	\$ (2,411)	1,624,297	\$ (17,439)	\$ 393,516
Net income				15,679				15,679
Other comprehensive (loss) income					(1,446)			(1,446)
Issuance of common stock for stock options exercised	66,571	1	2,951					2,952
Vested restricted stock units	7,493	—						—
Vested performance-based restricted stock units	5,859	—						—
Repurchase of common stock for net settlement of equity awards						4,797	(460)	(460)
Stock-based compensation expense			2,092					2,092
Common stock dividend paid				(5,711)				(5,711)
Balance at March 31, 2026	24,476,827	\$ 245	\$ 233,450	\$ 194,683	\$ (3,857)	1,629,094	\$ (17,899)	\$ 406,622
Net income				17,050				17,050
Other comprehensive income (loss)					(308)			(308)
Issuance of common stock for stock options exercised	16,703	—	776					776
Vested restricted stock units	672	—						—
Repurchase of common stock for net settlement of equity awards						173	(17)	(17)
Stock-based compensation expense			1,935					1,935
Common stock dividend paid				(5,716)				(5,716)
Balance at June 30, 2026	24,494,202	\$ 245	\$ 236,161	\$ 206,017	\$ (4,165)	1,629,267	\$ (17,916)	\$ 420,342

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensiv e Income (Loss)	Treasury Stock		Total Stockholders' Equity
	Shares	Amount				Shares	Amount	
Balance at December 31, 2024	24,153,165	\$ 242	\$ 213,760	\$ 145,090	\$ (6,184)	1,603,825	\$ (15,618)	\$ 337,290
Net income				11,011				11,011
Other comprehensive income (loss)					1,031			1,031
Issuance of common stock for stock options exercised	33,465	—	1,312					1,312
Vested restricted stock units	9,638	—						—
Vested performance-based restricted stock units	7,923	—						—
Repurchase of common stock for net settlement of equity awards						6,065	(601)	(601)
Stock-based compensation expense			2,046					2,046
Common stock dividend paid				(4,517)				(4,517)
Balance at March 31, 2025	24,204,191	\$ 242	\$ 217,118	\$ 151,584	\$ (5,153)	1,609,890	\$ (16,219)	\$ 347,572
Net income				13,779				13,779
Other comprehensive income (loss)					2,155			2,155
Issuance of common stock for stock options exercised	42,485	—	1,760					1,760
Vested restricted stock units	147	—						—
Repurchase of common stock for net settlement of equity awards						52	(4)	(4)
Stock-based compensation expense			1,944					1,944
Common stock dividend paid				(4,520)				(4,520)
Balance at June 30, 2025	24,246,823	\$ 242	\$ 220,822	\$ 160,843	\$ (2,998)	1,609,942	\$ (16,223)	\$ 362,686

See accompanying notes to consolidated financial statements.

LeMaitre Vascular, Inc.
Consolidated Statements of Cash Flows
(unaudited)

	For the six months ended June 30,	
	2026	2025
	(in thousands)	
Operating activities		
Net income	\$ 32,729	\$ 24,790
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	5,285	5,200
Stock-based compensation	4,027	3,990
Amortization of issuance costs on convertible senior notes	446	433
Non-cash investment income	(805)	—
Provision for inventory write-downs	1,548	1,030
Provision for credit losses	333	337
Foreign currency transaction effect on income	145	(279)
Changes in operating assets and liabilities:		
Accounts receivable	(2,877)	(5,299)
Inventory and other deferred costs	(1,935)	(3,454)
Prepaid expenses and other assets	(1,363)	1,676
Accounts payable and other liabilities	(6,475)	(1,250)
Accrued interest	—	2,156
Net cash provided by operating activities	31,058	29,330
Investing activities		
Purchases of short-term marketable securities	(231,434)	(17,849)
Purchases of property and equipment	(5,096)	(2,725)
Payments related to acquisitions, net of cash acquired	(158)	(95)
Proceeds from short-term marketable securities	212,489	—
Net cash used in investing activities	(24,199)	(20,669)
Financing activities		
Proceeds from stock option exercises	3,728	3,072
Deferred payments for acquisitions	(95)	(1,433)
Payment of withholding taxes in connection with net settlement of equity awards	(477)	(605)
Common stock cash dividend paid	(11,427)	(9,037)
Net cash used in financing activities	(8,271)	(8,003)
Effect of exchange rate changes on cash and cash equivalents	(207)	909
Net (decrease) increase in cash and cash equivalents	(1,619)	1,567
Cash and cash equivalents at beginning of period	28,244	25,610
Cash and cash equivalents at end of period	\$ 26,625	\$ 27,177
Non-cash operating activities		
Right-of-use assets obtained in exchange for new operating lease obligations	\$ 6,233	\$ 788
Supplemental cash flow information		
Cash paid for amounts included in the measurement of operating lease liabilities	\$ 2,683	\$ 1,580
Cash paid for interest	\$ 2,156	\$ —
Cash paid for income taxes	\$ 11,251	\$ 6,671

See accompanying notes to consolidated financial statements.

LeMaitre Vascular, Inc.
Notes to Consolidated Financial Statements
June 30, 2026
(unaudited)

1. Basis of Presentation and Summary of Significant Accounting Policies

Overview

Unless the context requires otherwise, references to LeMaitre, LeMaitre Vascular, and the Company refer to LeMaitre Vascular, Inc. and its subsidiaries. The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company's financial position as of June 30, 2026, and results of operations for the three- and six-months ended June 30, 2026 and 2025, and cash flows for the six months ended June 30, 2026 and 2025, have been made. The Company's results of operations for the three- and six-months ended June 30, 2026, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2026.

Significant Accounting Policies

A summary of the Company's significant accounting policies is included in Note 1 of the "Notes to Consolidated Financial Statements" contained in its Form 10-K for the year ended December 31, 2025. The Company believes that the consistent application of these policies enables it to provide users of the financial statements with useful and reliable information about its operating results and financial condition.

Beginning in 2026, the Company is self-insured for certain employee health benefits up to specified retention levels for its US-based employees. The Company records an expense as incurred with a liability for self-insured risks based on its estimate of the ultimate cost of both reported claims and claims incurred but not yet reported as of the balance sheet date. Expenses are allocated to the applicable employee department on the consolidated statement of operations and liabilities are recorded to accrued expenses on the consolidated balance sheet.

The estimation of self-insurance liabilities is a significant accounting estimate because it requires judgment and is subject to inherent uncertainty. Key assumptions used in estimating the liability include historical claims experience, claim development patterns, severity and frequency of claims, changes in healthcare costs, legal or regulatory developments, and other factors that may influence the ultimate cost of settling claims. The Company also uses information provided by third-party administrators and independent actuarial specialists in developing these estimates.

There have been no other significant changes during the three- and six-months ended June 30, 2026 in any of the Company's Significant Accounting Policies from those contained in its Form 10-K for the year ended December 31, 2025.

Recently Adopted Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments. The new guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The guidance is effective for fiscal years beginning after December 15, 2025, including interim reporting periods within those annual reporting periods, with early adoption permitted, and it can be adopted either on a prospective or retrospective basis. The Company adopted ASU 2024-04 effective

January 1, 2026, on a prospective basis. The adoption did not have a material impact on the Company's consolidated financial statements.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Modifications to Receivable and Contract Assets. The new guidance reduces the cost and complexity of applying the current expected credit loss model to current accounts receivable and current contract assets for public business entities through a practical expedient to assume that current conditions as of the balance sheet date will continue for the remaining life of assets. The guidance is effective for fiscal years beginning after December 15, 2025, including interim periods within those annual periods, with early adoption permitted on a prospective basis. The Company adopted ASU 2025-05 effective January 1, 2026 and elected the practical expedient. The adoption did not have a material impact on the Company's consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The new guidance modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs and enhances disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2027, including interim periods within those annual periods, with early adoption permitted, and it can be adopted either on a prospective or retrospective basis. During the quarter ended June 30, 2026, the Company adopted ASU 2025-06 effective January 1, 2026, on a prospective basis. The adoption did not have a material impact on the Company's consolidated financial statements.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company's annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvement. The new guidance creates a comprehensive list of required interim disclosures and incorporates a disclosure principle that requires disclosures at interim periods when an event or change that has a material effect on an entity has occurred since the previous year end. The guidance is effective for interim periods within fiscal years beginning after December 15, 2027 and it can be adopted either on a prospective or retrospective basis. The Company is currently in the process of evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures.

2. Investments

Investment Components

The Company invests in short-term marketable securities which include money markets held in the investment portfolios, equity securities, and available-for-sale debt securities. Available-for-sale debt securities are carried at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Interest, dividends, and realized gains and losses are recorded in investment income and other income (loss) on the statement of operations.

The components of investments consisted of the following:

	Fair Value Level	Amortized Cost Basis	Gross Unrealized Gain (in thousands)	Gross Unrealized Loss	Fair Value
June 30, 2026					
Corporate debt securities	Level 2	\$ 185,590	\$ 5	\$ (534)	\$ 185,061
United States government agency securities	Level 2	49,522	—	(316)	49,206
Asset-backed securities	Level 2	37,268	—	(77)	37,191
Yankee debt securities	Level 2	15,670	—	(28)	15,642
Commercial paper	Level 2	16,411	1	(26)	16,386
Certificates of deposit	Level 2	4,020	—	(2)	4,018
Total debt investments		308,481	6	(983)	307,504
Money market investments	Level 1	42,111	—	—	42,111
Total short-term marketable securities		\$ 350,592	\$ 6	\$ (983)	\$ 349,615

	Fair Value Level	Amortized Cost Basis	Gross Unrealized Gain (in thousands)	Gross Unrealized Loss	Fair Value
December 31, 2025					
Corporate debt securities	Level 2	\$ 168,802	\$ 46	\$ (102)	\$ 168,746
United States government agency securities	Level 2	53,380	43	—	53,423
Asset-backed securities	Level 2	33,249	35	(1)	33,283
Yankee debt securities	Level 2	10,599	7	(3)	10,603
Commercial paper	Level 2	5,618	4	—	5,622
Certificates of deposit	Level 2	1,595	1	—	1,596
Total debt investments		273,243	136	(106)	273,273
Equity investments	Level 1	19,997	—	—	19,997
Money market investments	Level 1	37,606	—	—	37,606
Total short-term marketable securities		\$ 330,846	\$ 136	\$ (106)	\$ 330,876

As of June 30, 2026, certain available-for-sale securities were in an unrealized loss position. The Company does not intend to sell, and it is more-likely-than-not that the Company will not be required to sell, these securities before recovery of their amortized cost basis. Accordingly, the Company concluded that no credit losses were required to be recognized as of June 30, 2026.

Contractual Maturities

The contractual maturities of available-for-sale debt securities as of June 30, 2026 were as follows:

	June 30, 2026	
	Amortized Cost Basis	Fair Value
	(in thousands)	
Due in one year or less	\$ 243,523	\$ 243,040
Due after one year through five years	107,069	106,575
Total	\$ 350,592	\$ 349,615

3. Inventory and Other Deferred Costs

Inventory and other deferred costs consisted of the following:

	June 30, 2026	December 31, 2025
	(in thousands)	
Raw materials	\$ 20,105	\$ 20,892
Work-in-process	2,850	2,922
Finished products	34,986	34,432
Other deferred costs	12,562	12,176
Total inventory and other deferred costs	\$ 70,503	\$ 70,422

The Company had inventory on consignment at customer sites of \$1.5 million and \$1.6 million as of June 30, 2026, and December 31, 2025, respectively.

In connection with the Company's RestoreFlow allograft business, other deferred costs include costs incurred for the preservation of human tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the tissues the Company preserves are not held as inventory, and the costs the Company incurs to procure and process vascular tissues are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials, and facilities costs. The Company expenses general and administrative expenses and selling expenses associated with the provision of these services as incurred.

4. Goodwill and Other Intangible Assets

There was no change to goodwill during the six months ended June 30, 2026. Other intangible assets consisted of the following:

	June 30, 2026			December 31, 2025		
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
	(in thousands)					
Product technology and intellectual property	\$ 29,549	\$ 22,432	\$ 7,117	\$ 29,549	\$ 21,290	\$ 8,259
Trademarks, tradenames and licenses	3,767	2,745	1,022	3,767	2,599	1,168
Customer relationships	39,513	17,787	21,726	39,366	16,356	23,010
Other intangible assets	2,393	1,714	679	2,255	1,603	652
Total identifiable intangible assets	<u>\$ 75,222</u>	<u>\$ 44,678</u>	<u>\$ 30,544</u>	<u>\$ 74,937</u>	<u>\$ 41,848</u>	<u>\$ 33,089</u>

Intangible assets consist primarily of customer relationships, purchased developed technology, trademarks, licenses, and non-compete provisions, and are amortized over their estimated useful lives. The weighted-average amortization period for these intangibles as of June 30, 2026, is 7.8 years. The Company includes amortization expense in general and administrative expense as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Amortization expense	<u>\$ 1,415</u>	<u>\$ 1,437</u>	<u>\$ 2,830</u>	<u>\$ 2,857</u>

Estimated amortization expense for the remainder of 2026, and for each of the next five fiscal years, based upon intangible assets at June 30, 2026, is as follows:

	Year ended December 31,				
	2026	2027	2028	2029	2030
	(in thousands)				
Amortization expense	<u>\$ 2,806</u>	<u>\$ 5,340</u>	<u>\$ 4,883</u>	<u>\$ 4,839</u>	<u>\$ 3,797</u>
					<u>\$ 2,662</u>

5. Accrued Expenses and Other Long-term Liabilities

Accrued expenses consisted of the following:

	June 30, 2026	December 31, 2025
	(in thousands)	
Compensation and related taxes	\$ 11,878	\$ 18,286
Accrued inventory purchases	4,256	4,197
Accrued expenses	3,568	2,752
Accrued interest	1,797	1,797
Income and other taxes	849	1,661
Professional fees	231	172
Other	301	546
Total	<u>\$ 22,880</u>	<u>\$ 29,411</u>

Other long-term liabilities consisted of the following:

	June 30, 2026	December 31, 2025
	(in thousands)	
Acquisition-related liabilities	609	624
Income taxes	485	504
Other	365	340
Total	<u>\$ 1,459</u>	<u>\$ 1,468</u>

6. Income Taxes

As part of the process of preparing its consolidated financial statements, the Company is required to determine its income taxes in each of the jurisdictions in which it operates. This process involves the Company estimating its actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the Company's consolidated balance sheet. The Company must then assess the likelihood that its deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. To the extent the Company establishes a valuation allowance or increases its allowance in a period, the Company must reflect this increase as an expense within the tax provision in the statement of operations. The Company does not provide for income taxes on undistributed earnings of certain foreign subsidiaries, as its intention is to permanently reinvest these earnings.

The Company recognizes, measures, presents, and discloses in its consolidated financial statements any uncertain tax positions that it has taken, or expects to take on a tax return. The Company operates in multiple taxing jurisdictions, both inside and outside the United States, and may be subject to audits from various tax authorities. Management's judgment is required in determining the Company's provision for income taxes, deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against the Company's net deferred tax assets. The Company monitors the realizability of its deferred tax assets and will adjust the valuation allowance accordingly.

The Company's policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense. The Company's 2026 income tax expense varies from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, different statutory rates from its foreign subsidiaries, and discrete stock option exercises. The Company's 2025 income tax expense varied from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, different statutory rates from its foreign subsidiaries, and discrete stock option exercises.

The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. As of June 30, 2026, the gross amount of unrecognized tax benefits exclusive of interest and penalties was \$0.4 million. The Company remains subject to examination until the statute of limitations expires for each remaining respective tax

jurisdiction. The statute of limitations will be open with respect to these tax positions until 2031. A reconciliation of the beginning and ending amount of the Company's unrecognized tax benefits is as follows:

	Six months ended June 30, 2026 (in thousands)
Unrecognized tax benefits as of December 31, 2025	\$ 410
Additions/adjustments for tax positions of current year	—
Additions/adjustments for tax positions of prior years	7
Reductions for settlements with taxing authorities	—
Reductions for lapses of the applicable statutes of limitations	—
Unrecognized tax benefits as of June 30, 2026	<u>\$ 417</u>

As of June 30, 2026, a summary of the tax years that remain subject to examination in the Company's taxing jurisdictions is as follows:

United States	2022 and forward
Foreign	2017 and forward

7. Convertible Senior Notes

Convertible senior notes consisted of the following:

	June 30, 2026 (in thousands)	December 31, 2025 (in thousands)
Principal amount of convertible senior notes	\$ 172,500	\$ 172,500
Less: Current portion of convertible senior notes	—	—
Convertible senior notes, net of current portion	172,500	172,500
Debt discount, net of accretion	(3,409)	(3,855)
Convertible senior notes, net of discount and current portion	<u>\$ 169,091</u>	<u>\$ 168,645</u>

On December 19, 2024, the Company issued \$172.5 million aggregate principal amount of convertible senior notes due 2030 (the "Senior Convertible Notes"), in a Rule 144A private placement to qualified institutional buyers pursuant to an indenture dated December 19, 2024, by and between the Company and U.S. Bank Trust Company, National Association (the "Indenture").

The Senior Convertible Notes will mature on February 1, 2030, unless earlier repurchased, redeemed, or converted. The proceeds from the issuance of the Senior Convertible Notes were approximately \$167.7 million, net of initial purchaser discounts and other debt issuance costs totaling \$4.8 million.

The Senior Convertible Notes bear interest at a rate of 2.50% per year and interest is payable semiannually in arrears on August 1 and February 1 of each year. For the six months ended June 30, 2026, the Company made \$2.2 million in interest payments. The Company did not make any interest payments for the six months ended June 30, 2025. The initial conversion rate was 8.3521 shares of common stock per \$1,000 principal amount of the Senior Convertible Notes, which represents an initial conversion price of approximately \$119.73 per share of common stock and a premium of approximately 30% over the closing price of the Company's common stock on December 16, 2024. In connection with the most recent payment made by the Company on June 4, 2026 of a quarterly cash dividend of \$0.25 per share (an increase from the quarterly dividend amount of \$0.16 per share as of the time of issuance of the Senior Convertible Notes), the conversion rate of the Senior Convertible Notes was increased to 8.3820 shares of common stock per \$1,000 principal amount of the Senior Convertible Notes, which represents a conversion price of approximately \$119.30 per share of common stock. A similar adjustment to the conversion rate will be made by the Company upon payment of the quarterly cash dividend of \$0.25 on September 3, 2026, and upon payment of subsequent quarterly dividends in excess of \$0.16 per share. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events as described in the Indenture.

Noteholders may convert all or a portion of their Senior Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2025, if the last reported sale price per share of

the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period in which the trading price per \$1,000 principal amount of Senior Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as described in the Indenture; (4) if the Company calls (or is deemed to have called) any Senior Convertible Notes for redemption; and (5) at any time from, and including, August 1, 2029, until the close of business on the second scheduled trading day immediately before the maturity date. The Company has the right to elect to settle conversions either in cash, shares of its common stock, or in a combination of cash and shares of its common stock.

Additional interest of up to 0.5% per annum is payable if the Company fails to timely file required documents or reports with the SEC or the Senior Convertible Notes cease to be freely tradable (as defined in the Indenture). The Company determined that the higher interest payments required in certain circumstances were embedded derivatives that should be bifurcated and accounted for at fair value. The Company assessed the value of the embedded derivatives at each balance sheet date and determined they had de minimis value.

Prior to February 5, 2028, the Senior Convertible Notes will not be redeemable. On or after February 5, 2028, until the 40th trading day immediately before the maturity date, the Company may redeem for cash all or any portion of the Senior Convertible Notes (subject to the partial redemption limitation set forth in the Indenture), at its option, if the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30-consecutive-trading-day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption. In addition, calling any Senior Convertible Note for redemption will constitute a "Make-Whole Fundamental Change" (as defined in the Indenture) with respect to that Senior Convertible Note, in which case the conversion rate applicable to the conversion of that Senior Convertible Note will be increased in certain circumstances if it is converted after it is called for redemption.

During the six months ended June 30, 2026, the Company recognized \$2.2 million in interest expense related to the 2.50% cash coupon of the Senior Convertible Notes and \$0.4 million of amortization expense of the debt issuance costs. During the six months ended June 30, 2025, the Company recognized \$2.2 million in interest expense related to the 2.50% cash coupon of the Senior Convertible Notes and \$0.4 million of amortization expense of the debt issuance costs. As of June 30, 2026, the estimated fair value of the Senior Convertible Notes was \$183.3 million compared to \$172.3 million as of December 31, 2025. The fair value was determined based on the quoted price of the last trade of the Senior Convertible Notes prior to the end of the reporting period in an inactive market, which is considered as Level 2 in the fair value hierarchy.

8. Stock-Based Compensation

The Company's Fourth Amended and Restated 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, performance-based restricted stock units, unrestricted stock awards, and deferred stock awards to its officers, employees, directors, and consultants. The components of stock-based compensation expense included in the consolidated statements of operations are as follows:

	Three months ended		Six months ended	
	June 30,		June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Stock option awards	\$ 813	\$ 910	\$ 1,677	\$ 1,810
Restricted stock units	688	634	1,357	1,320
Performance-based restricted stock units	434	400	993	860
Total stock-based compensation	<u>\$ 1,935</u>	<u>\$ 1,944</u>	<u>\$ 4,027</u>	<u>\$ 3,990</u>

Stock-based compensation is included in the Company's consolidated statements of operations as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Cost of sales	\$ 320	\$ 266	\$ 609	\$ 552
Sales and marketing	304	349	611	725
General and administrative	1,140	1,140	2,412	2,316
Research and development	171	189	395	397
Total stock-based compensation	<u>\$ 1,935</u>	<u>\$ 1,944</u>	<u>\$ 4,027</u>	<u>\$ 3,990</u>

During the six months ended June 30, 2026, the Company granted 520 restricted stock units. The Company did not grant any options or performance-based restricted stock units during the six months ended June 30, 2026. During the six months ended June 30, 2025, the Company granted 741 options, 1,521 restricted stock units, and 129 performance-based restricted stock units. The Company issued 97,298 and 93,658 shares of common stock following the exercise or vesting of underlying stock options, restricted stock units, and performance-based restricted stock units during the six months ended June 30, 2026 and 2025, respectively.

9. Net Income per Share

Basic net income per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income per share reflects the potential dilution that could occur from securities or other contracts to issue common stock, including senior convertible notes, stock options, restricted stock units, and performance-based restricted stock units. Diluted net income per share for the Company's convertible senior notes is calculated using the if-converted method. Under this method, interest expense, net of tax, associated with the convertible senior notes is added back to net income and the shares issuable upon conversion are included in diluted weighted-average shares outstanding.

A reconciliation of the numerators and the denominators of the basic and dilutive net income per common share computations are as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands, except per share data)		(in thousands, except per share data)	
Numerator:				
Net income - basic	\$ 17,050	\$ 13,779	\$ 32,729	\$ 24,790
Effect of dilutive shares on net income				
Interest expense on convertible senior notes, net of tax	1,001	—	2,035	—
Net income - diluted	\$ 18,051	\$ 13,779	\$ 34,764	\$ 24,790
Denominator:				
Weighted average basic common shares outstanding	22,858	22,614	22,830	22,592
Effect of dilutive securities:				
Options to purchase common stock	160	210	168	235
Restricted stock units	34	40	30	39
Performance-based restricted stock units	36	28	34	30
Convertible senior notes	1,443	—	1,443	—
Weighted average dilutive common shares outstanding	24,531	22,892	24,505	22,896
Net income per share:				
Basic	\$ 0.75	\$ 0.61	\$ 1.43	\$ 1.10
Diluted	\$ 0.74	\$ 0.60	\$ 1.42	\$ 1.08

During the three- and six-months ended June 30, 2026, the Company had \$172.5 million principal amount of 2.5% Senior Convertible Notes outstanding. The Senior Convertible Notes were assumed converted at the beginning of the reporting period for purposes of calculating diluted net income per share. Accordingly, the Company added back \$1.0 million and \$2.0 million of after-tax interest expense to the numerator and included 1.4 million shares issuable upon conversion in the denominator for the three- and six-months ended June 30, 2026. Because the effect of the assumed conversion was dilutive, the Senior Convertible Notes were included in the computation of diluted net income per share. There was no dilutive effect on the calculations for the three- and six-months ended June 30, 2025.

The Company has excluded potential dilutive securities from the computation of diluted earnings per common share that would be anti-dilutive to net income per common share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net income per common share attributable to common shareholders for the periods indicated because including them would have an anti-dilutive effect:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Convertible senior notes	—	1,442	—	1,442
Options to purchase common stock	290	126	293	126
Restricted stock units	—	32	—	32
Performance-based restricted stock units	—	10	—	10
	<u>290</u>	<u>1,610</u>	<u>293</u>	<u>1,610</u>

10. Stockholders' Equity

Share Repurchase Program

On February 19, 2026, the Company's Board of Directors authorized the repurchase of up to \$100.0 million of the Company's common stock through transactions on the open market, in privately negotiated purchases, or otherwise until February 18, 2027. The repurchase program may be suspended or discontinued at any time. To date the Company has not made any repurchases under this program.

Dividends

In February 2011, the Company's Board of Directors approved a policy for the payment of quarterly cash dividends on its common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

	Record Date	Payment Date	Per Share Amount	Dividend Payment (in thousands)
Fiscal Year 2026				
	March 12, 2026	March 26, 2026	\$ 0.25	\$ 5,711
	May 21, 2026	June 4, 2026	\$ 0.25	\$ 5,716
Fiscal Year 2025				
	March 13, 2025	March 27, 2025	\$ 0.20	\$ 4,517
	May 15, 2025	May 29, 2025	\$ 0.20	\$ 4,520
	August 21, 2025	September 4, 2025	\$ 0.20	\$ 4,535
	November 20, 2025	December 4, 2025	\$ 0.20	\$ 4,538

On July 28, 2026, the Company's Board of Directors approved a quarterly cash dividend on its common stock of \$0.25 per share payable on September 3, 2026, to stockholders of record at the close of business on August 20, 2026.

11. Commitments and Contingencies

Operating Leases

The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, manufacturing, and distribution, as well as automobiles and printing equipment. As of June 30, 2026, the Company had the following building and facility leases capitalized on the balance sheet:

Location (leases)	Purpose	Expiration
Americas		
Vaughan, Canada	Canada sales office and distribution	August 2026
Fox River Grove, IL (2)	RestoreFlow allografts business	December 2026
North Brunswick, NJ	Artegraft biologic business	October 2029
Burlington, MA (2)	Corporate headquarters and US distribution	December 2030
Billerica, MA	US distribution	December 2032
Burlington, MA (4)	Corporate headquarters and manufacturing	December 2034
Mississauga, Canada	Canada sales office and distribution	March 2036
Europe, Middle East and Africa		
Milan, Italy	Italy sales office and distribution	September 2027
Madrid, Spain	Spain sales office and distribution	June 2029
Hereford, England	United Kingdom sales office and distribution	October 2029
Maisons-Alfort, France	France sales office and distribution	February 2030
Glattbrugg, Switzerland	Switzerland sales office and distribution	February 2030
Dublin, Ireland	Ireland sales office and distribution	September 2030
Sulzbach, Germany	European headquarters and distribution	June 2031
Asia Pacific		
Bangkok, Thailand	Thailand sales office and distribution	August 2026
Seoul, Korea	Korea sales office and distribution	April 2027
Tokyo, Japan	Japan sales office and distribution	July 2027
Shanghai, China	China sales office and distribution	October 2027
Singapore	Asia Pacific headquarters and distribution	June 2028
Docklands, Australia	Australia sales office and distribution	April 2030
Ballarat, Australia	Supply facility	December 2030

Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future lease minimum payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

None of the Company's noncancelable lease payments include non-lease components such as maintenance contracts. The Company generally reimburses the landlord for direct operating costs associated with the leased space. The Company has no subleases, and there are no residual value guarantees associated with, or restrictive covenants imposed by, any of its leases. The Company held no assets under finance leases as of June 30, 2026. The Company elected the package of practical expedients that allow it to omit leases with initial terms of 12 months or less from its balance sheet, which the Company expenses on a straight-line basis over the life of the lease.

The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis.

Additional information with respect to the Company's leases is as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Lease cost				
Operating lease cost	\$ 1,325	\$ 447	\$ 2,662	\$ 1,041
Short-term lease cost	20	20	50	46
Total lease cost	<u>\$ 1,345</u>	<u>\$ 467</u>	<u>\$ 2,712</u>	<u>\$ 1,087</u>
Weighted average remaining lease term - operating leases (in years)			6.5	6.9
Weighted average discount rate - operating leases			6.48%	6.62%

As of June 30, 2026, the minimum noncancelable operating lease rental commitments with initial or remaining terms of more than one year are as follows:

Remainder of 2026	\$ 2,441
Year ending December 31,	
2027	4,284
2028	3,949
2029	3,792
2030	3,294
2031	2,564
Thereafter	6,025
Adjustment to net present value as of June 30, 2026	(5,186)
Minimum noncancelable lease liability	<u>\$ 21,163</u>

12. Segment and Geographic Information

The Company regularly reviews its segment financial information and the approach used by the chief operating decision maker ("CODM"), the Chief Executive Officer, to evaluate performance and allocate resources. The Company considers the business to be a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients, all used primarily in the field of vascular surgery.

The CODM assesses performance for its single operating segment and decides how to allocate resources based on net income that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.

The CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the single operating segment or into other parts of the entity, such as for acquisitions, dividend payments, and/or short-term marketable security investments. Net income is also used to monitor budget versus actual results, which is used in assessing performance of the segment and in establishing management's compensation.

In addition to total segment net income, the CODM's quarterly reporting package includes several highlighted expense categories that the CODM considers key strategic drivers of the Company's long-term profitability. The following is the Company's operating segment reconciliation of net income, including significant segment expenses:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Net sales	\$ 70,382	\$ 64,232	\$ 136,933	\$ 124,103
Cost of sales	19,618	19,258	37,773	37,709
Gross profit	50,764	44,974	99,160	86,394
Less:				
Selling expense	12,845	13,579	25,645	26,403
Marketing expense	1,563	1,316	3,278	2,704
Administrative expense	7,526	7,177	15,489	14,000
Finance expense	2,647	2,481	5,831	5,449
Management information systems expense	937	738	1,836	1,434
Research and development expense	1,472	1,113	2,895	2,214
Process engineering expense	1,338	543	2,340	1,282
Regulatory and clinical expense	2,037	1,885	3,672	4,140
Other (income) expense, net*	3,349	2,363	5,445	3,978
Net income	<u>\$ 17,050</u>	<u>\$ 13,779</u>	<u>\$ 32,729</u>	<u>\$ 24,790</u>

*Refer to the consolidated statement of operations for the components of other income and expense and related amounts.

Most of the Company's revenues are generated in the United States, Germany, the United Kingdom, other European countries, and Canada. Substantially all of the Company's assets are located in the United States and Germany. Net sales to unaffiliated customers based on customer location by country were as follows:

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
United States	\$ 38,250	\$ 36,656	\$ 75,436	\$ 71,284
Germany	5,341	4,458	10,879	8,435
Canada	4,551	3,955	8,604	7,676
United Kingdom	3,725	3,296	6,851	6,445
Other countries	18,515	15,867	35,163	30,263
Net sales	<u>\$ 70,382</u>	<u>\$ 64,232</u>	<u>\$ 136,933</u>	<u>\$ 124,103</u>

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February 26, 2026, or the 2025 Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the "Item 1A. Risk Factors" section of this Quarterly Report on Form 10-Q and the "Item 1A. Risk Factors" section of our 2025 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada, and Asia Pacific, or APAC. We estimate that the annual worldwide market for peripheral vascular devices exceeds \$9 billion, within which we estimate that the market for our products is approximately \$1 billion. We have grown our business using a three-pronged strategy: 1) pursuing a focused call point, 2) competing for sales of low-rivalry, niche products, and 3) expanding our worldwide direct sales force while acquiring complementary devices. We have used acquisitions as a primary means of further penetrating the peripheral vascular device market, and we expect to continue this strategy in the future. We currently manufacture most of our products in our Burlington, Massachusetts headquarters.

Our products and services are used primarily by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and therefore can provide a wider range of treatment options to their patients. Recently we have also begun to explore adjacent market customers, such as cardiac surgeons and interventional cardiologists.

Our principal product lines include the following: anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Through our RestoreFlow allografts business, we also process and cryopreserve human vascular and cardiac tissue.

Our principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. In Q2 2026, biologics represented 55% of our worldwide sales. We believe our biologic devices represent differentiated and, in many cases, growing product segments.

Our business opportunities include the following:

- growing our direct sales force in North America, Europe, and APAC, including replacing distributors with our direct sales personnel;
- increasing the average selling prices of our devices;
- introducing our products into new territories upon receipt of regulatory approvals or registrations;
- acquiring complementary products and transitioning distributor sales to LeMaitre;
- updating existing products and introducing new products through research and development; and
- consolidating product manufacturing into our Burlington, Massachusetts facilities.

We sell our products and services primarily through a direct sales force. Our worldwide headquarters is located in Burlington, Massachusetts, and we also have a North American sales office in Vaughan, Canada. We are moving our North American sales office to Mississauga, Canada in Q3 2026. Our European headquarters is located in Sulzbach, Germany, and we also have European sales offices in Milan, Italy; Madrid, Spain; Hereford, England; Dublin, Ireland; Maisons-Alfort, France; and Glattbrugg, Switzerland. Our APAC headquarters is located in Singapore, and we also have APAC sales offices in Tokyo, Japan; Shanghai, China; Docklands, Australia; Seoul, Korea; and Bangkok, Thailand. During the quarter ended June 30, 2026, approximately 95% of our net sales were generated in territories in which we employ direct sales representatives. We sell our products in other countries through distributors. As of June 30, 2026, our sales force comprised 163 sales representatives and export managers in North America, Europe, and APAC.

Historically we have experienced success in lower-rivalry niche segments. In the valvulotome market, for example, our differentiated devices have historically allowed us to increase average selling prices without incurring significant unit share loss. In contrast, we have experienced less success in competitive markets such as the polyester vascular graft market, where we face competition from larger companies with greater resources and lower per unit costs.

We have also experienced success in international markets, such as Europe, where we have a significant sales force, and sometimes offer lower average selling prices than in North America. If we continue to seek growth opportunities outside of North America, we may experience downward pressure on our gross margin.

We obtain regulatory approvals for our devices and services in new product categories and geographies to further access the broader peripheral device market and selected other markets, thus extending our geographic reach. Recent approvals include clearance to sell the Artegraft bovine graft in the European Union (EU) in April 2025, Australia in June 2025, and Canada in December 2025, the Pruitt Aortic Occlusion Catheter in the EU in May 2025, and the Pruitt Occlusion Catheter in China in June 2025.

Separately, our regulatory efforts to maintain approvals in the EU and the United Kingdom (UK) have succeeded ahead of the full EU transition from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) and the UK transition to the United Kingdom Conformity Assessed (UKCA) mark. As of June 30, 2026, we have substantially all of our product approvals in the EU and UK. The European Commission has designated the end of 2028 as the final MDR CE mark transition deadline.

Historically, we have provided cryopreservation services for our RestoreFlow allografts primarily in the US, UK, and Canada. In October 2025, we received approval from the German authority on tissue banking to allow provision of these services in the German market. We began providing cryopreservation services for our RestoreFlow allografts in Germany in May 2026.

Our strategy for growing our business includes acquisitions of complementary product lines and companies, which can be difficult to identify, negotiate, and purchase. There can be no assurance that we will be able to do so in the future.

- In December 2025, we entered into an agreement with Andramed GmbH to purchase the assets of their AndraValvulotome business for \$1.8 million plus additional payments of up to \$0.8 million, contingent upon the passage of time and, separately, receipt of a regulatory approval.

Occasionally we discontinue or divest products that are no longer complementary to our business or not commercially viable.

- During 2025, we made the decision to terminate our cardiovascular porcine patch distribution agreement with Elutia. Previously, in April 2023, we had entered into an agreement with Elutia to become the exclusive U.S. distributor of their cardiovascular porcine patches. Under the agreement, we could distribute the products for three years with an option to acquire Elutia's worldwide cardiovascular porcine patch business during the second and third years of the agreement. This product totaled approximately \$1.8 million in 2025 revenues.
- During 2025, we made the decision to wind down the CardioCel 3D and DuraSure product lines. These product lines totaled approximately \$0.5 million in 2025 revenues.
- During 2025, we made the decision to wind down the AnastoClip AC Closure System in North America. This product totaled approximately \$0.7 million in 2025 revenues.

From time to time we may undertake SKU reductions and attempt to transition sales to other SKUs or products with similar features. Any of these actions may result in inventory write-offs and temporary or permanent negative impacts to our sales, gross margin, and customer relationships.

- During 2026, we made the decision to wind down the Flexcel single-size pack offerings to simplify our Flexcel portfolio while continuing to offer the Flexcel multi-size packs to customers. These Flexcel single-size product packs totaled approximately \$0.9 million in revenue for the six months ended June 30, 2026.

Because we believe that direct-to-hospital sales engender closer customer relationships, and allow for higher selling prices and gross margins through elimination of an intermediary, we periodically enter into transactions with country-specific distributors to transition their sales of our medical devices into our direct sales organization:

- In March 2025, we entered into a distribution transition agreement with our Portuguese distributor to sell products directly in Portugal and dissolve the existing distribution arrangement. We have been selling direct-to-hospitals in Portugal since May 2025. The distribution termination fees are expected to total approximately \$0.2 million.
- In June 2025, we entered into a distribution transition agreement with our Czech distributor to sell products directly in Czechia and dissolve the existing distribution arrangement. We have been selling direct-to-hospitals in Czechia since July 2025. The distribution termination fees are expected to total approximately \$0.1 million.
- In 2026, in conjunction with the purchase of the AndraValvulotome assets from Andramed GmbH, we entered into several distribution transition agreements with existing distributors of the product line in European countries, including those in Germany, France, Italy, the UK, and other smaller markets. We have been selling direct-to-hospitals in these countries subsequent to the execution of the transition agreements in 2026. The total distribution termination fees for all AndraValvulotome related distributors are expected to total approximately \$0.5 million.

In addition to our sales growth strategies, we have also executed several operational initiatives designed to consolidate manufacturing into our Burlington facilities. We expect these plant consolidations and manufacturing transfers will result in improved control over production quality as well as reduced costs. Our most recent manufacturing transfers are:

- In October 2019, we acquired the CardioCel and VascuCel biologic patch businesses from Anteris. The transfer to Burlington was substantially completed in 2023. In June 2023, the MDR CE mark application for these Burlington-produced devices was submitted, and we obtained approval in January 2025, allowing for distribution of these patches in the EU. We began distributing these Burlington-produced patches in the United States, Canada, and select APAC markets in 2024.
- In February 2026, we announced the transition of our allograft tissue processing from our Fox River Grove facility to Burlington. This transition is expected to be substantially complete by the end of 2026.

Our execution of these initiatives may affect the comparability of our financial results and may cause fluctuations from period to period.

In February 2024, we began implementing a new enterprise resource planning, or ERP, system to replace our financial reporting and planning system. In the United States, we transitioned from our legacy ERP system to our newly implemented Microsoft Dynamics D365 system in February 2024. We implemented this new system in the UK in February 2025, Ireland in April 2026, and Canada in July 2026. We intend to continue rolling out the new system in our other international locations on a staged basis. The new ERP system has been beneficial in a number of areas, including inventory management, pricing programs, financial operations and real-time reporting. As of June 30, 2026, we have net capitalized costs on our balance sheet of \$4.7 million associated with this ERP system.

Fluctuations in the exchange rates between the U.S. dollar and foreign currencies, primarily the Euro, affect our financial results. For the six months ended June 30, 2026, approximately 45% of our sales took place outside of the United States, largely in currencies other than the U.S. dollar. We expect foreign currencies will represent a significant percentage of future sales. Selling, marketing, and administrative costs related to these sales are also denominated in foreign currencies, thereby partially mitigating our bottom-line exposure to exchange rate fluctuations. If there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require less of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases we will record more revenue in U.S. dollars than we would have if the exchange rate had not changed. For the six months ended June 30, 2026, we estimate that the effects of changes in foreign exchange rates increased our reported sales by approximately \$2.4 million, as compared to rates in effect for the six months ended June 30, 2025.

Net Sales and Expense Components

The following is a description of the primary components of our net sales and expenses:

Net sales. We derive our net sales from the sale of our products and services, less discounts and returns. Net sales include the shipping and handling fees paid for by our customers. Most of our sales are generated by our direct sales force and are shipped and billed to hospitals or clinics globally. In countries where we do not have a direct sales force, sales are primarily to distributors, who in turn sell to hospitals and clinics. In limited cases our products are held on consignment at a hospital or clinic prior to purchase; in those instances we recognize revenue at the time the product is used in surgery rather than at shipment.

Cost of sales. We manufacture the majority of the products that we sell. Our cost of sales consists primarily of manufacturing personnel wages, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, including an allocation of our quality department expenses. Additionally, cost of sales includes the freight expenses we pay to ship products to customers, inventory scrap charges, and excess and obsolescence expenses.

Sales and marketing. Sales and marketing expense consists primarily of salaries, commissions, contests, stock-based compensation, travel and entertainment, sales meetings, attendance at vascular and cardiac congresses, training programs, advertising and product promotions, direct mail, and other marketing costs. Additionally, sales and marketing expense includes customer service department personnel charges.

General and administrative. General and administrative expense consists primarily of executive, finance and human resource salaries, stock-based compensation, legal and accounting fees, information technology expense, intangible asset amortization expense, and insurance expense.

Research and development. Research and development expense primarily includes costs associated with obtaining and maintaining regulatory approval of our products, salaries, laboratory testing, and supply costs. It also includes costs associated with the design and execution of clinical studies and costs to transfer the manufacturing of acquired product lines to our Burlington facility. Additionally, research and development expense includes costs associated with the design, development, testing, and enhancement of new or existing products.

Other income (expense). Other income (expense) primarily includes interest and dividend income, realized gains (losses) from the sale of debt and equity investments, unrealized gains (losses) from equity investments, interest expense for the Senior Convertible Notes, foreign currency gains (losses), and other miscellaneous gains (losses).

Income tax expense. We are subject to federal and state income taxes for earnings generated in the United States, which include operating losses or profits in certain foreign jurisdictions for certain years depending on tax elections made, and foreign taxes on earnings of our wholly-owned foreign subsidiaries. Our consolidated tax expense is affected by the mix of our taxable income (loss) in the United States and foreign subsidiaries, permanent items, discrete items, unrecognized tax benefits, and amortization of goodwill for U.S. tax reporting purposes.

Results of Operations

Comparison of the three- and six-month periods ended June 30, 2026, to the three- and six-month periods ended June 30, 2025:

The following table sets forth for the periods indicated our net sales by geography and the change between the specified periods expressed as a percentage increase or decrease:

(unaudited)	Three months ended June 30,			Six months ended June 30,		
	2026	2025	Percent change	2026	2025	Percent change
	(in thousands)			(in thousands)		
Net sales	\$ 70,382	\$ 64,232	10%	\$ 136,933	\$ 124,103	10%
Net sales by geography:						
Americas	\$ 43,454	\$ 41,321	5%	\$ 85,050	\$ 80,279	6%
Europe, Middle East and Africa	22,137	18,840	18%	42,424	35,799	19%
Asia Pacific	4,791	4,071	18%	9,459	8,025	18%
Total	<u>\$ 70,382</u>	<u>\$ 64,232</u>	<u>10%</u>	<u>\$ 136,933</u>	<u>\$ 124,103</u>	<u>10%</u>

Net sales. Net sales increased by \$6.2 million, or 10%, to \$70.4 million for the three months ended June 30, 2026, compared to \$64.2 million for the three months ended June 30, 2025. The increase was driven primarily by higher average selling prices, higher unit volumes shipped to customers, and the European launch of Artegraft in the second half of 2025. Graft sales increased \$5.1 million, shunt sales increased \$1.1 million, and patches sales increased \$0.6 million. Catheter sales decreased \$0.9 million due to the increased sales volumes related to the April 2025 recall of our TufTex Over-the-Wire, Pruitt Occlusion, and Pruitt Irrigation catheters. We estimate that the weaker U.S. dollar increased net sales by \$0.4 million during the three months ended June 30, 2026, as compared to the three months ended June 30, 2025.

Direct-to-hospital net sales were 95% of our total net sales for both the three months ended June 30, 2026 and 2025.

Net sales increased by \$12.8 million, or 10%, to \$136.9 million for the six months ended June 30, 2026, compared to \$124.1 million for the six months ended June 30, 2025. The increase was driven by higher average selling prices, higher unit volumes shipped

to customers, and the European launch of Artegraft in the second half of 2025. Graft sales increased \$9.2 million, shunt and valvulotome sales each increased \$1.8 million, and clip sales increased \$1.0 million, offset by decreased sales of catheters of \$0.4 million, decreased sales of tape of \$0.3 million, and decreased sales of patches of \$0.2 million due to the termination of our distribution agreement with Elutia in 2025. We estimate that the weaker U.S. dollar increased net sales by \$2.4 million during the six months ended June 30, 2026, as compared to the six months ended June 30, 2025.

Direct-to-hospital net sales were 95% and 94% of our total net sales for the six months ended June 30, 2026 and 2025.

Net sales by geography. Net sales in the Americas increased \$2.1 million, or 5%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. The increase was driven primarily by increased sales of grafts of \$2.4 million, shunts and patches of \$0.3 million each, and valvulotomes of \$0.1 million, offset by decreased sales of catheters of \$0.7 million.

Net sales in the Americas increased \$4.8 million, or 6%, for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025. The increase was driven primarily by increased sales of grafts of \$5.4 million, valvulotomes of \$0.6 million, and shunts of \$0.5 million, offset by decreased sales of patches of \$1.1 million, due to the termination of our distribution agreement with Elutia in 2025, and catheters of \$0.6 million.

Net sales in Europe, Middle East, and Africa, or EMEA, increased \$3.3 million, or 18%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. The increase was driven primarily by increased sales of grafts of \$2.5 million, shunts of \$0.7 million, patches of \$0.3 million, and valvulotomes of \$0.1 million, offset by decreased sales of catheters of \$0.4 million.

Net sales in EMEA increased \$6.6 million, or 19%, for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025. The increase was driven primarily by increased sales of grafts of \$3.5 million, shunts of \$1.2 million, valvulotomes of \$1.1 million, and patches of \$0.7 million.

Net sales in APAC increased \$0.7 million, or 18%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. The increase was driven primarily by increased sales of clips, grafts, and catheters of \$0.2 million each and shunts of \$0.1 million.

Net sales in APAC increased \$1.4 million, or 18%, for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025. The increase was driven primarily by increased sales of clips of \$0.5 million, grafts of \$0.3 million, patches, catheters, and shunts of \$0.2 million each, and valvulotomes of \$0.1 million.

Gross Profit. The following table sets forth the change in our gross profit and gross margin for the periods indicated:

(unaudited)	Three months ended June 30,				Six months ended June 30,			
	2026	2025	Change	Percent change	2026	2025	Change	Percent change
	(in thousands)				(in thousands)			
Gross profit	\$ 50,764	\$ 44,974	\$ 5,790	13%	\$ 99,160	\$ 86,394	\$ 12,766	15%
Gross margin	72.1%	70.0%	2.1%	*	72.4%	69.6%	2.8%	*

* Not applicable

Gross profit increased \$5.8 million, or 13%, to \$50.8 million for the three months ended June 30, 2026, as compared to \$45.0 million for the three months ended June 30, 2025, and gross margin increased by 210 basis points to 72.1% in the period, as compared to 70.0% for the three months ended June 30, 2025. The increase in gross profit was driven primarily by increased sales, particularly from grafts, shunts, and patches. The increase in gross margin was driven primarily by sales price increases, favorable product mix, and lower shipping costs. The increase was partially offset by unfavorable manufacturing efficiencies and higher excess and obsolescence charges during the period.

Gross profit increased \$12.8 million, or 15%, to \$99.2 million for the six months ended June 30, 2026, as compared to \$86.4 million for the six months ended June 30, 2025, and gross margin increased by 280 basis points to 72.4% in the period, as compared to 69.6% for the six months ended June 30, 2025. The increase in gross profit was driven primarily by increased sales, particularly from grafts, shunts, and valvulotomes. The increase in gross margin was driven primarily by sales price increases, favorable product mix, including decreased sales of comparatively lower margin porcine patches due to the decision to end our distribution agreement with

Elutia, and lower shipping costs. The increase was partially offset by higher scrap and excess and obsolescence charges during the period.

Operating Expenses. The following tables set forth changes in our operating expenses for the periods indicated and the change between the specified periods expressed as a percentage increase or decrease:

(unaudited)	Three months ended June 30,				Six months ended June 30,			
	2026	2025	\$ Change	Percent change	2026	2025	\$ Change	Percent change
	(in thousands)				(in thousands)			
Sales and marketing	\$ 14,408	\$ 14,895	\$ (487)	(3)%	\$ 28,923	\$ 29,107	\$ (184)	(1)%
General and administrative	11,110	10,396	714	7%	23,156	20,883	2,273	11%
Research and development	4,847	3,541	1,306	37%	8,907	7,636	1,271	17%
Total	\$ 30,365	\$ 28,832	\$ 1,533	5%	\$ 60,986	\$ 57,626	\$ 3,360	6%

	Three months ended June 30,			Six months ended June 30,		
	2026	2025	Change	2026	2025	Change
	% of Net Sales	% of Net Sales		% of Net Sales	% of Net Sales	
Sales and marketing	20%	23%	(3)%	21%	23%	(2)%
General and administrative	16%	16%	0%	17%	17%	0%
Research and development	7%	6%	1%	7%	6%	1%

Sales and marketing. For the three months ended June 30, 2026, sales and marketing expenses decreased 3% to \$14.4 million. The decrease was driven primarily by lower compensation and related expenses of \$0.4 million, including lower commissions and contest expenses of \$0.2 million. Sales force headcount was 163 as of June 30, 2026, a 2% increase from June 30, 2025. As a percentage of net sales, sales and marketing expenses decreased to 20% for the three months ended June 30, 2026, down from 23% for the three months ended June 30, 2025.

For the six months ended June 30, 2026, sales and marketing expenses decreased 1% to \$28.9 million. The decrease was driven primarily by lower commissions and contest expenses of \$0.5 million, offset by increased sales meetings and trade show expenses of \$0.3 million. As a percentage of net sales, sales and marketing expenses decreased to 21% for the six months ended June 30, 2026, down from 23% for the six months ended June 30, 2025.

General and administrative. For the three months ended June 30, 2026, general and administrative expenses increased 7% to \$11.1 million. The increase was driven primarily by higher headcount and wage increases, which resulted in increased compensation and related expenses of \$0.5 million. Professional fees and outside services expenses increased \$0.4 million, offset by decreased travel and training expenses of \$0.1 million. As a percentage of net sales, general and administrative expenses remained consistent at 16% for the three months ended June 30, 2026 and 2025, respectively.

For the six months ended June 30, 2026, general and administrative expenses increased 11% to \$23.2 million. The increase was driven primarily by higher headcount and wage increases, which resulted in increased compensation and related expenses of \$1.3 million. Professional fees and outside services expenses increased \$0.8 million and general supplies expenses increased \$0.5 million, offset by lower facility expenses of \$0.2 million. As a percentage of net sales, general and administrative expenses remained consistent at 17% for the six months ended June 30, 2026 and 2025, respectively.

Research and development. For the three months ended June 30, 2026, research and development expenses increased 37% to \$4.8 million. The increase was driven primarily by higher third-party service fees and general supplies associated with the current transfer of our allograft tissue processing from our Fox River Grove facility to Burlington, which resulted in increased expenses of \$0.9 million. Facility expenses increased \$0.4 million due to start-up costs associated with the new Billerica shipping warehouse since the inception of the lease beginning on January 1, 2026. The transfer of shipping operations to the Billerica shipping warehouse started in June 2026. As a percentage of net sales, research and development expenses increased to 7% for the three months ended June 30, 2026, up from 6% for the three months ended June 30, 2025.

For the six months ended June 30, 2026, research and development expenses increased 17% to \$8.9 million. The increase was driven primarily by higher facility expenses of \$0.6 million, general supplies expenses of \$0.5 million, and professional fees and outside services expenses of \$0.1 million. As a percentage of net sales, research and development expenses increased to 7% for the six months ended June 30, 2026, up from 6% for the six months ended June 30, 2025.

Income tax expense. We recorded a tax provision of \$5.1 million on pre-tax income of \$22.2 million for the three months ended June 30, 2026, compared to a \$4.3 million tax provision on pre-tax income of \$18.1 million for the three months ended June 30, 2025. We recorded a tax provision of \$9.1 million on pre-tax income of \$41.9 million for the six months ended June 30, 2026, compared to a tax provision of \$7.5 million on pre-tax income of \$32.3 million for the six months ended June 30, 2025. Our effective income tax rate was 23.2% and 21.8% for the three- and six-month periods ended June 30, 2026. Our tax expense for the current period is based on an estimated annual effective tax rate of 22.8%, adjusted in the applicable quarterly periods for discrete stock option exercises and other discrete items. Our income tax expense for the current period varies from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, different statutory rates from our foreign entities, and a discrete item for stock option exercises.

Our effective income tax rate was 23.7% and 23.3% for the three- and six-month periods ended June 30, 2025. Our 2025 provision was based on the estimated annual effective tax rate of 23.8%, adjusted in the applicable quarterly period for discrete stock option exercises and other discrete items. Our income tax expense for the three- and six-month periods ended June 30, 2025 varied from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, different statutory rates from our foreign entities, and a discrete item for stock option exercises.

We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed. While it is often difficult to predict the final outcome or timing of the resolution for any particular tax matter, we believe our tax reserves reflect the probable outcome of known contingencies.

We assess the likelihood that our deferred tax assets will be realized through future taxable income and record a valuation allowance to reduce gross deferred tax assets to an amount that we believe is more likely than not to be realized. As of June 30, 2026, we have provided a valuation allowance of \$1.7 million for deferred tax assets primarily related to Australian net operating loss and capital loss carry forwards and Massachusetts tax credit carry forwards that are not expected to be realized.

On July 4, 2025, President Donald Trump signed the One Big Beautiful Bill Act ("OBBBA") into law. Key corporate tax provisions include the restoration of 100% bonus depreciation for qualifying assets, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to GILTI and FDII rules, amendments to energy credits, and expanded Section 162(m) aggregation requirements. The impact of these adjustments is reflected in our tax provision and financial statements for the three- and six-month periods ended June 30, 2026. We will continue to monitor future legislative developments and assess their impact on our tax position and financial reporting.

Liquidity and Capital Resources

As of June 30, 2026, our cash and cash equivalents were \$26.6 million, as compared to \$28.2 million as of December 31, 2025. We had \$349.6 million in short-term marketable securities as of June 30, 2026, as compared to \$330.9 million as of December 31, 2025. Our cash and cash equivalents are bank deposits and liquid investments with maturities of 90 days or less at the date of purchase held in our operating bank accounts. Our short-term marketable securities primarily include corporate debt securities, U.S. government agency securities, and money market investments with maturities of 90 days or less at the date of purchase held outside of our operating bank accounts. As of June 30, 2026, our short-term marketable securities reflected an unrealized loss of \$1.0 million as a result of market interest rates.

On February 19, 2026, our Board of Directors authorized the repurchase of up to \$100.0 million of our common stock through transactions on the open market, in privately negotiated purchases, or otherwise until February 18, 2027. The repurchase program may be suspended or discontinued at any time. To date we have not made any repurchases under this or any prior program.

Convertible Senior Notes

On December 19, 2024, we issued \$172.5 million aggregate principal amount of convertible senior notes due 2030, or the Senior Convertible Notes, in a Rule 144A private placement to qualified institutional buyers pursuant to an indenture dated December 19, 2024, by and between us and U.S. Bank Trust Company, National Association, or the Indenture.

The Senior Convertible Notes will mature on February 1, 2030, unless earlier repurchased, redeemed or converted. The proceeds from the issuance of the Senior Convertible Notes were approximately \$167.7 million, net of debt issuance costs totaling \$4.8 million. The Senior Convertible Notes bear interest at a rate of 2.50% per year, and interest is payable semiannually in arrears on August 1 and

February 1 of each year. For the six months ended June 30, 2026, we made \$2.2 million in interest payments. We did not make any interest payments for the six months ended June 30, 2025. The initial conversion rate is 8.3521 shares of common stock per \$1,000 principal amount of the Senior Convertible Notes, which represented an initial conversion price of approximately \$119.73 per share of common stock and a premium of approximately 30% over the closing price of our common stock on December 16, 2024. In connection with the most recent payment made on June 4, 2026 of a quarterly cash dividend of \$0.25 per share (an increase from the quarterly dividend amount of \$0.16 per share as of the time of issuance of the Senior Convertible Notes), the conversion rate of the Senior Convertible Notes was increased to 8.3820 shares of common stock per \$1,000 principal amount of the Senior Convertible Notes, which represents a conversion price of approximately \$119.30 per share of common stock. A similar adjustment to the conversion rate will be made upon payment of the quarterly cash dividend of \$0.25 on September 3, 2026, and upon payment of subsequent quarterly dividends in excess of \$0.16 per share. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events as described in the Indenture.

Noteholders may convert all or a portion of their Senior Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2025, if the last reported sale price per share of our common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period in which the trading price per \$1,000 principal amount of Senior Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the Indenture; (4) if we call (or are deemed to have called) any Senior Convertible Notes for redemption; and (5) at any time from, and including, August 1, 2029, until the close of business on the second scheduled trading day immediately before the maturity date. We have the right to elect to settle conversions either in cash, shares of common stock, or in a combination of cash and shares of our common stock.

Prior to February 5, 2028, the Senior Convertible Notes will not be redeemable. On or after February 5, 2028, until the 40th scheduled trading day immediately before the maturity date, we may redeem for cash all or any portion of the Senior Convertible Notes (subject to the partial redemption limitation set forth in the Indenture), at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption. In addition, calling any Senior Convertible Note for redemption will constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) with respect to that Senior Convertible Note, in which case the conversion rate applicable to the conversion of that Senior Convertible Note will be increased in certain circumstances if it is converted after it is called for redemption.

Operating and Capital Expenditure Requirements

We require cash to pay our operating expenses, make capital expenditures, and pay our long-term liabilities. Since our inception, we have funded our operations through public offerings and private placements of equity securities, short-term and long-term borrowings, and funds generated from our operations.

We recognized operating income of \$38.2 million for the six months ended June 30, 2026, compared to \$28.8 million for the six months ended June 30, 2025. We expect to fund any increased costs and expenditures from our existing cash and cash equivalents and short-term marketable securities, though our future capital requirements depend on numerous factors. These factors include, but are not limited to, the following:

- revenues generated by sales of our products and services;
- costs associated with expanding our manufacturing, marketing, sales, and distribution efforts;
- payments associated with potential future quarterly cash dividends to our common stockholders;
- payments associated with income and other taxes;
- future acquisition-related payments;
- costs associated with our initiatives to sell direct-to-hospital in new countries;
- costs of obtaining and maintaining FDA and other regulatory clearances;
- the number, timing, and nature of acquisitions, divestitures, and other strategic transactions; and
- potential future share repurchases.

We believe that our cash, cash equivalents, short-term marketable securities, and the interest we earn on these balances will enable us to fund our operating expenses, capital expenditures requirements, and Senior Convertible Note interest payments for at least twelve months following the filing of this Form 10-Q and, together with our anticipated future cash, cash equivalents, and short-term marketable securities, to meet our known long-term cash requirements.

We may need to raise additional funding, which might not be available on desirable terms or at all. See “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025.

Cash Flows

	Six months ended June 30,		
	2026	2025 (in thousands)	Net Change
Cash and cash equivalents	\$ 26,625	\$ 27,177	\$ (552)
Cash flows provided by (used in):			
Operating activities	\$ 31,058	\$ 29,330	\$ 1,728
Investing activities	(24,199)	(20,669)	(3,530)
Financing activities	(8,271)	(8,003)	(268)

Net cash provided by operating activities. Net cash provided by operating activities was \$31.1 million for the six months ended June 30, 2026, consisting of \$32.7 million in net income, adjusted for non-cash items of \$11.0 million (including primarily depreciation and amortization of \$5.3 million, stock-based compensation of \$4.0 million, provisions for inventory write-offs and credit losses of \$1.9 million, amortization of issuance costs on convertible senior notes of \$0.4 million, foreign currency transaction effect on income of \$0.1 million, offset by non-cash investment income of \$0.8 million), and a net use of working capital of \$12.7 million. The net cash used for working capital was driven by decreases in accounts payable and other liabilities of \$6.5 million, increases in accounts receivable of \$2.9 million, increases in inventory and other deferred costs of \$1.9 million, and increases in prepaid expenses and other assets of \$1.4 million.

Net cash provided by operating activities was \$29.3 million for the six months ended June 30, 2025, consisting of \$24.8 million in net income, adjusted for non-cash items of \$10.7 million (including primarily depreciation and amortization of \$5.2 million, stock-based compensation of \$4.0 million, provisions for inventory write-offs and credit losses of \$1.4 million, and amortization of issuance costs on convertible senior notes of \$0.4 million, offset by foreign currency effect on income of \$0.3 million), and net use of working capital of \$6.2 million. The net cash used for working capital was driven by increases in accounts receivable of \$5.3 million, increases in inventory and other deferred costs of \$3.5 million, and decreases in accounts payable and other liabilities of \$1.3 million, offset by increases in accrued interest of \$2.2 million and decreases in prepaid expenses and other liabilities of \$1.7 million.

Net cash used in investing activities. Net cash used in investing activities was \$24.2 million for the six months ended June 30, 2026, consisting of purchases of short-term marketable securities of \$231.4 million, purchases of property and equipment of \$5.1 million, and payments related to acquisitions of \$0.2 million, offset by proceeds from short-term marketable securities of \$212.5 million.

Net cash used in investing activities was \$20.7 million for the six months ended June 30, 2025, consisting of purchases of short-term marketable securities of \$17.8 million, purchases of property and equipment of \$2.7 million, and payments related to acquisitions of \$0.1 million.

Net cash used in financing activities. Net cash used in financing activities was \$8.3 million for the six months ended June 30, 2026, consisting of dividend payments of \$11.4 million and deferred payments for acquisitions of \$0.1 million, offset by proceeds from stock option exercises of \$3.3 million, net of shares repurchased to pay employee payroll taxes.

Net cash used in financing activities was \$8.0 million for the six months ended June 30, 2025, consisting of dividend payments of \$9.0 million and deferred payments for acquisitions of \$1.4 million, offset by proceeds from stock option exercises of \$2.5 million, net of shares repurchases to pay employee payroll taxes.

Dividends

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

Record Date	Payment Date	Per Share Amount	Dividend Payment (in thousands)
Fiscal Year 2026			
March 12, 2026	March 26, 2026	\$ 0.25	\$ 5,711
May 21, 2026	June 4, 2026	\$ 0.25	\$ 5,716
Fiscal Year 2025			
March 13, 2025	March 27, 2025	\$ 0.20	\$ 4,517
May 15, 2025	May 29, 2025	\$ 0.20	\$ 4,520
August 21, 2025	September 4, 2025	\$ 0.20	\$ 4,535
November 20, 2025	December 4, 2025	\$ 0.20	\$ 4,538

On July 28, 2026, our Board of Directors approved a quarterly cash dividend on its common stock of \$0.25 per share payable on September 3, 2026, to stockholders of record at the close of business on August 20, 2026.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. We evaluate our estimates on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates from those disclosed in our consolidated financial statements and the related notes and other financial information included in our 2025 Form 10-K.

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed in Note 1 to our consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to changes in interest rates and foreign currency exchange rates because we denominate our transactions in a variety of foreign currencies. Changes in these rates may have an impact on future cash flow and earnings. We manage these risks through normal operating and financing activities. There has been no material change in the foreign currency risk or interest rate risk discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in “Quantitative and Qualitative Disclosure About Market Risk” included in our 2025 Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2026, our Chief

Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

As previously disclosed, in February 2024 we began implementing a new ERP system. The ERP implementation requires the integration of new ERP software with multiple new data flows and business processes. The new ERP is designed to accurately maintain our books and records and provide information to our management teams which is important to the operations of the business. As the phased implementation of the new ERP system progresses, we expect to continue to change certain processes and procedures which, in turn, are expected to result in changes to our internal control over financial reporting. As such changes occur, we will evaluate quarterly whether such changes materially affect our internal control over financial reporting.

Other than the new ERP system implementation, there have been no changes to our internal control over financial reporting during the quarter ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to employment, product liability, commercial arrangements, contracts, intellectual property and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters that management believes would have a material adverse effect on our financial position, results of operations, or cash flows.

Item 1A. Risk Factors

In addition to the information set forth in this report, you should consider the risks and uncertainties discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition, or future results. The risk factors below supplement and update the risk factors and information discussed in our Annual Report on Form 10-K for the year ended December 31, 2025.

Even after our products have received marketing approval or clearance, our products and the tissue we process may be subject to recall. Licenses, registrations, approvals, and clearances could be withdrawn or suspended due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval.

Our products, services, marketing, sales, development activities, and manufacturing processes are subject to extensive and rigorous regulation by the FDA, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. If those regulatory bodies believe that we have failed to comply with regulatory standards, there can be no assurance that any approval, licensure, or registration will not be subsequently withdrawn, suspended or conditioned upon extensive post-market study requirements, even after having received marketing approval or clearance or licenses and registrations. Further, due to the interconnectedness of the various regulatory agencies, particularly within the EU, there is also no assurance that withdrawal or suspension of any of our approvals, licenses, or registrations by any single regulatory agency will not cause one or more additional regulatory agencies to also withdraw or suspend their approval, license, or registration.

In the event that any of our products prove to be defective, we can voluntarily recall, or the FDA or foreign equivalent could require us to recall, any of our products. In the EU and UK, adverse event reporting requirements mandate that we report incidents which led or could have led to death or serious deterioration in health. Recalls, whether voluntary or required, could result in significant costs to us and significant adverse publicity. In severe instances, the FDA may also issue a warning letter, require the destruction of defective product, and/or order the suspension or cessation of manufacturing of defective product. Additionally, if someone is harmed by a malfunction or a product defect, we may experience product liability claims for such defects. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital and may harm our financial results. Future recalls or claims could also result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future. For example, in April 2025, we voluntarily notified our regulatory bodies of an inadequate seal on the packaging of our TufTex Over-the-Wire, Pruitt Occlusion, and Pruitt Irrigation catheters, which may result in a compromised sterile barrier. Notice was provided to each of our customers of the inadequate seal, and customers were offered a product replacement for any existing inventory on hand. The financial impact of the voluntary notification is not expected to be material to our business. Additionally, in August 2025, the FDA issued a warning letter to us following an April 2025 inspection of our Artergast facility in North Brunswick. In August 2025, we responded to the cited observations and since then have continued to implement corrective actions. In June 2026, the FDA concluded a re-inspection of our Artergast facility and identified additional new inspectional observations, without commenting on the April 2025 cited observations. We have submitted responses to the FDA regarding these observations, continue to engage with the agency concerning the status of our remediation efforts and the warning letter, and expect to incur ongoing costs and devote management resources to addressing these matters. We believe that the FDA will likely inspect our Artergast facility again to review our corrective action activities. To date, the financial impact of the warning letter and related regulatory activities has not been material to our business, and there has been no disruption to Artergast sales. However, there can be no assurance that the FDA will find our corrective actions satisfactory, that additional inspections will not result in further observations or in enforcement actions, or that these matters will not adversely affect our operations, regulatory compliance, reputation or financial results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**Recent Sales of Unregistered Securities**

None.

Issuer Purchases of Equity Securities

Issuer Purchases of Equity Securities				Maximum Number (or Approximate Dollar Value) of Shares (or Units) that may yet be Purchased under the Plans or Program (2)
Period	Total Number of Shares (or Units) Purchased (1)	Average Price Paid Per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Program	
April 1, 2026 through April 30, 2026	34	\$ 108.75	N/A	\$ 100,000,000
May 1, 2026 through May 31, 2026	139	\$ 96.37	N/A	\$ 100,000,000
June 1, 2026 through June 30, 2026	—	\$ —	N/A	\$ 100,000,000
Total	173	\$ 98.80	N/A	

- (1) For the three months ended June 30, 2026, we repurchased 173 shares of our common stock to satisfy employees' obligations with respect to minimum statutory withholding taxes in connection with the vesting of restricted stock units and performance-based restricted stock units.
- (2) On February 19, 2026, our Board of Directors authorized the repurchase of up to \$100.0 million of our common stock through transactions on the open market, in privately negotiated purchases, or otherwise until February 18, 2027. To date, we have not made any repurchases under this program.

Item 5. Other Information**Rule 10b5-1 and non-Rule 10b5-1 trading arrangements**

None.

Item 6. Exhibits

Exhibit Number	Exhibit Description	Incorporated by Reference			Filed Herewith
		Form	Date	Number	
31.1	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
31.2	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
32.1†	Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
32.2†	Certification by the Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema with embedded Linkbase Documents.				X
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).				X

† This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 5, 2026.

LEMAITRE VASCULAR, INC.

/s/ George W. LeMaitre

George W. LeMaitre

Chairman and Chief Executive Officer

/s/ Dorian P. LeBlanc

Dorian P. LeBlanc

Chief Financial Officer

EXHIBIT 31.1
CERTIFICATION

I, George W. LeMaitre, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LeMaitre Vascular, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ George W. LeMaitre

George W. LeMaitre
Chairman and Chief Executive Officer
(Principal Executive Officer)

Date: August 5, 2026

EXHIBIT 31.2
CERTIFICATION

I, Dorian P. LeBlanc, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LeMaitre Vascular, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Dorian P. LeBlanc

Dorian P. LeBlanc

Chief Financial Officer

(Principal Accounting and Financial Officer)

Date: August 5, 2026

EXHIBIT 32.1

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “*Exchange Act*”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), George W. LeMaitre, Chairman and Chief Executive Officer of LeMaitre Vascular, Inc. (the “*Company*”), certifies to the best of his knowledge that:

- (1) The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “*Report*”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. § 1350 and is not deemed to be a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

/s/ George W. LeMaitre

George W. LeMaitre
Chairman and Chief Executive Officer
(Principal Executive Officer)
August 5, 2026

EXHIBIT 32.2

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “*Exchange Act*”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dorian P. LeBlanc, Chief Financial Officer of LeMaitre Vascular, Inc. (the “*Company*”), certifies to the best of his knowledge that:

- (1) The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “*Report*”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. § 1350 and is not deemed to be a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

/s/ Dorian P. LeBlanc

Dorian P. LeBlanc

Chief Financial Officer

(Principal Accounting and Financial Officer)

August 5, 2026
